Abstract
Physicians are often approached by young women with a BRCA mutation and a recent history of breast cancer who wish to have a baby. They wish to know if pregnancy impacts upon their future risks of cancer recurrence and survival. To date, there is little information on the survival experience of women who carry a mutation in one of the BRCA genes and who become pregnant. From an international multi-center cohort study of 12,084 women with a BRCA1 or BRCA2 mutation, we identified 128 case subjects who were diagnosed with breast cancer while pregnant or who became pregnant after a diagnosis of breast cancer. These women were age-matched to 269 mutation carriers with breast cancer who did not become pregnant (controls). Subjects were followed from the date of breast cancer diagnosis until the date of last follow-up or death from breast cancer. The Kaplan-Meier method was used to estimate 15-year survival rates. The hazard ratio for survival associated with pregnancy was calculated using a left-truncated Cox proportional hazard model, adjusting for other prognostic factors. Among women who were diagnosed with breast cancer when pregnant or who became pregnant thereafter, the 15-year survival rate was 91.5 %, compared to a survival of 88.6 % for women who did not become pregnant (adjusted hazard ratio = 0.76; 95 % CI 0.31-1.91; p = 0.56). Pregnancy concurrent with or after a diagnosis of breast cancer does not appear to adversely affect survival among BRCA1/2 mutation carriers.
| Original language | English |
|---|---|
| Pages (from-to) | 177-185 |
| Number of pages | 9 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 142 |
| Issue number | 1 |
| DOIs | |
| State | Published - Nov 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. / Valentini, Adriana; Lubinski, Jan; Byrski, Tomasz; Ghadirian, Parviz; Moller, Pal; Lynch, Henry T.; Ainsworth, Peter; Neuhausen, Susan L.; Weitzel, Jeffrey; Singer, Christian F.; Olopade, Olufunmilayo I.; Saal, Howard; Lyonnet, Dominique Stoppa; Foulkes, William D.; Kim-Sing, Charmaine; Manoukian, Siranoush; Zakalik, Dana; Armel, Susan; Senter, Leigha; Eng, Charis; Grunfeld, Eva; Chiarelli, Anna M.; Poll, Aletta; Sun, Ping; Narod, Steven A.
In: Breast Cancer Research and Treatment, Vol. 142, No. 1, 11.2013, p. 177-185.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation
AU - Valentini, Adriana
AU - Lubinski, Jan
AU - Byrski, Tomasz
AU - Ghadirian, Parviz
AU - Moller, Pal
AU - Lynch, Henry T.
AU - Ainsworth, Peter
AU - Neuhausen, Susan L.
AU - Weitzel, Jeffrey
AU - Singer, Christian F.
AU - Olopade, Olufunmilayo I.
AU - Saal, Howard
AU - Lyonnet, Dominique Stoppa
AU - Foulkes, William D.
AU - Kim-Sing, Charmaine
AU - Manoukian, Siranoush
AU - Zakalik, Dana
AU - Armel, Susan
AU - Senter, Leigha
AU - Eng, Charis
AU - Grunfeld, Eva
AU - Chiarelli, Anna M.
AU - Poll, Aletta
AU - Sun, Ping
AU - Narod, Steven A.
PY - 2013/11
Y1 - 2013/11
N2 - Physicians are often approached by young women with a BRCA mutation and a recent history of breast cancer who wish to have a baby. They wish to know if pregnancy impacts upon their future risks of cancer recurrence and survival. To date, there is little information on the survival experience of women who carry a mutation in one of the BRCA genes and who become pregnant. From an international multi-center cohort study of 12,084 women with a BRCA1 or BRCA2 mutation, we identified 128 case subjects who were diagnosed with breast cancer while pregnant or who became pregnant after a diagnosis of breast cancer. These women were age-matched to 269 mutation carriers with breast cancer who did not become pregnant (controls). Subjects were followed from the date of breast cancer diagnosis until the date of last follow-up or death from breast cancer. The Kaplan-Meier method was used to estimate 15-year survival rates. The hazard ratio for survival associated with pregnancy was calculated using a left-truncated Cox proportional hazard model, adjusting for other prognostic factors. Among women who were diagnosed with breast cancer when pregnant or who became pregnant thereafter, the 15-year survival rate was 91.5 %, compared to a survival of 88.6 % for women who did not become pregnant (adjusted hazard ratio = 0.76; 95 % CI 0.31-1.91; p = 0.56). Pregnancy concurrent with or after a diagnosis of breast cancer does not appear to adversely affect survival among BRCA1/2 mutation carriers.
AB - Physicians are often approached by young women with a BRCA mutation and a recent history of breast cancer who wish to have a baby. They wish to know if pregnancy impacts upon their future risks of cancer recurrence and survival. To date, there is little information on the survival experience of women who carry a mutation in one of the BRCA genes and who become pregnant. From an international multi-center cohort study of 12,084 women with a BRCA1 or BRCA2 mutation, we identified 128 case subjects who were diagnosed with breast cancer while pregnant or who became pregnant after a diagnosis of breast cancer. These women were age-matched to 269 mutation carriers with breast cancer who did not become pregnant (controls). Subjects were followed from the date of breast cancer diagnosis until the date of last follow-up or death from breast cancer. The Kaplan-Meier method was used to estimate 15-year survival rates. The hazard ratio for survival associated with pregnancy was calculated using a left-truncated Cox proportional hazard model, adjusting for other prognostic factors. Among women who were diagnosed with breast cancer when pregnant or who became pregnant thereafter, the 15-year survival rate was 91.5 %, compared to a survival of 88.6 % for women who did not become pregnant (adjusted hazard ratio = 0.76; 95 % CI 0.31-1.91; p = 0.56). Pregnancy concurrent with or after a diagnosis of breast cancer does not appear to adversely affect survival among BRCA1/2 mutation carriers.
UR - http://www.scopus.com/inward/record.url?scp=84888234523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888234523&partnerID=8YFLogxK
U2 - 10.1007/s10549-013-2729-1
DO - 10.1007/s10549-013-2729-1
M3 - Article
VL - 142
SP - 177
EP - 185
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 1
ER -